

Moncef Slaoui

Dr Moncef Slaoui, a Moroccan Belgian and American scientist, holds a PhD in Immunology. He spent a long career in vaccine and medicine research and development during which he was involved in the development of several vaccines including the first ever vaccine against Malaria. In 2020 he was the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the Operation enabled the fastest ever development manufacturing and approval of COVID19 vaccines.

He was Chairman of R&D at GSK where his career spanned almost 30 years. After retiring from GSK in 2017, he joined Medicxi ventures and since remained a dynamic force in life sciences, serving on the boards of several Biotechnology companies including Moderna and Vaxcyte (2017-2020). He currently chairs the boards of Altesa Arcturus and Curevo.

In 2016, Dr Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world.